Quarterly Activities and Cashflow Reports - March 23 Qtr
Filed with ASX · · 7 pages · English
Amplia Therapeutics Ltd. on 6ix
Story so far
Earlier from Amplia Therapeutics
- First Patient Recruited to Cohort 3 of ACCENT Trial
- Dose Escalation Approved in ACCENT Clinical Trial of AMP945
- First Patient Recruited to Cohort 2 of Accent Trial
- Quarterly Activities and Cashflow Reports - December 2022
- Letter to Shareholders End of Year Summary and 2023 Plans
Later from Amplia Therapeutics
- ACCENT Trial Recruitment Progress
- Amplia receives grant to collaborate with CSIRO
- Grant to collaborate with CSIRO Supplementary Announcement
- AMP945 and FOLFIRINOX active in model of Pancreatic Cancer
- Annual Report to Shareholders
Follow Amplia Therapeutics into a list and get an email when it puts out news.
Follow Amplia Therapeutics